Screening Platform: Compounds, Functional Genomics, and Therapeutics

The Screening Discovery Platform (SDP) provides expertise in the drug discovery pipeline for assay development and high-throughput screening. We have automated Screening Platforms in BSL2+ (Opera Phenix Plus, Operetta CLS, Ensight, Envision) / BSL3 (Operetta CLS, Nivo) to support research activities.

All types of assay models (phenotypic, target, 3D) can be run against our libraries for drug repositioning, new chemical entities, target ID, and MOA assessment.

  • Validating and formatting assays to 96/384/1536 well format to perform screening activities
  • Chemical library collection of 400K compounds identified as potential starting points for the development of novel therapeutics
  • Genomic platforms (siRNA and shRNA technology) to identify new targets and signaling pathways as well as uncover mechanism of actions
  • Advanced liquid handlers to support any workflow processes including Echo Acoustic Dispenser, Biomek, and Janus.

Development areas: High Throughput Screening, High Content Screening, Small Molecule, Drugs, Functional Genomics, Target ID & MOA, Ai-driven analysis.

It allows scientists to conduct cutting edge research in cellular and molecular biology, including real-time observation and study of cellular and subcellular interactions involved in the transmission of bacterial, parasitic, and viral diseases.

ARIADNE is composed of two platforms: ARIADNE-Criblage, High-Content and High-throughput-Screening Platform and ARIADNE-ADME.

Working independently but complementary, their objective is to discover small chemical molecules useful in therapy or to explore the living, and to characterize their ADME properties. ARIADNE-Criblage brings together a set of expertise and equipment dedicated to the screening of biological disruptors such as small chemical molecules or siRNA libraries. ARIADNE-ADME allows to quantify the parameters which characterize the ability of molecules to be Absorbed, Distributed, Metabolized and Eliminated in vivo (ADME). Evaluation of ADME parameters early in the discovery process is widely used during target validation, hit-discovery, hit-to-lead optimisation stages

We developed methods for detecting direct (binary) interactions between pairs of proteins, based on the complementation of luciferase enzymes (“split-luciferase”). We use these methods for high-throughput PPIs mapping in human cells (HEK293T). Our pipelines provide systematic, semi-quantitative and comparative PPIs maps. We are using the human ORFeome library, a collection of 17,000 human cDNAs, to gather pathway-dedicated sub-collections, i.e. an innate immunity-oriented library or a Ubiquitin Proteasome System library. The IRI laboratory focuses on virus/host PPIs, mainly studying respiratory and emerging viruses with the goal to identify molecular requisites of viral adaptation to human. We are open to collaborations for binary PPIs screening of our currently available libraries, for generating new human-proteome sub-libraries with any type of protein partners, should they be from a pathogen or not. Application of our PPIs screening pipeline to other organisms can be envisaged provided that orfeome of studied species are generated.

Target-based (High Throughput Screening, HTS) and phenotypic (High Content Screening, HCS) screening assays are powerful tools to identify active chemical substances and genetic modulators of function (siRNA, miRNA, gRNA) providing starting points for drug design or for understanding biological processes. Using liquid handling devices, sensitive detectors and data processing software, HTS/HCS allow a researcher to rapidly test a large number of samples.